A

ngered by a controversial Allergan patent maneuver, Sen. Claire McCaskill (D-Mo.) on Thursday introduced a bill that prohibits tribal sovereign immunity from being used to block certain types of patent challenges.

Her move comes after Allergan transferred six patents for its best-selling Restasis eye treatment last month to a Mohawk tribe, which has sovereign immunity and is now attempting to use its status to block patent challenges filed by several generic drug makers.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Changing the law is the only recourse. In 1998 the Supreme Court, in the case of the Kiowa tribe of Oklahoma vs Manufacturing Technologies, Inc. ruled that Sovereign Tribal Nations are immune from civil lawsuits.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy